Suresh Babu appointed as Business Unit Director – Eye Care at AbbVie India

AbbVie India has appointed Suresh Babu as Business Unit Director – Eye Care, marking a significant leadership elevation in the company’s ophthalmology franchise. The role positions Babu at the helm of AbbVie’s India‑eye‑care business, where he is expected to lead strategy, brand execution, and long‑term growth across the company’s ophthalmology portfolio, including medicines and solutions for conditions such as glaucoma, dry eye, and other sight‑threatening disorders.
According to CXO Lanes, Babu joins the role with over 25 years of professional experience in healthcare and life sciences leadership, including a strong track record in sales, marketing, and strategic business‑unit management. His background is expected to support AbbVie in strengthening its market position in ophthalmology, deepening relationships with key stakeholders such as hospitals, eye‑care foundations, and government‑ and private‑health‑systems, and aligning India‑level eye‑care strategy with AbbVie’s global ophthalmology and neuroscience priorities.
In the Indian context, where a large yet underserved patient base faces significant unmet needs in eye‑care, especially in glaucoma and dry‑eye, AbbVie’s focus is on expanding awareness programmes, enhancing access to therapy, and improving clinical‑practice pathways for early diagnosis. As Business Unit Director, Babu is likely to drive integrated campaigns that combine medical‑education initiatives, digital‑engagement tools, and patient‑support programmes to increase detection‑rates and adherence, while also guiding the commercial‑planning and pricing‑framework for AbbVie’s ophthalmology brands in a price‑sensitive and highly regulated market.
The appointment also reflects AbbVie’s broader push to build a robust leadership pipeline in India, where local‑leadership teams are being entrusted with greater strategic and financial‑accountability for global‑assets. Babu’s elevation reinforces the company’s intent to treat India not just as a large‑volume market but as a platform for shaping innovative eye‑care models that can feed insights into AbbVie’s regional and global strategies.